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Abstract
Background: Currently, there are no effective therapeutic options for Alzheimer’s disease, the most common,
multifactorial form of dementia, characterized by anomalous amyloid accumulation in the brain. Growing evidence
points to neuroinflammation as a major promoter of AD. We have previously shown that the proinflammatory
cytokine TNFSF10 fuels AD neuroinflammation, and that its immunoneutralization results in improved cognition in
the 3xTg-AD mouse.
Methods: Here, we hypothesize that inflammatory hallmarks of AD might parallel with central and peripheral
immune response dysfunction. To verify such hypothesis, we used a triple transgenic mouse model of AD. 3xTg-AD
mice were treated for 12 months with an anti-TNFSF10 antibody, and thereafter immune/inflammatory markers
including COX2, iNOS, IL-1β and TNF-α, CD3, GITR, and FoxP3 (markers of regulatory T cells) were measured in the
spleen as well as in the hippocampus.
Results: Spleens displayed accumulation of amyloid-β1–42 (Aβ1-42), as well as high expression of Treg cell markers
FoxP3 and GITR, in parallel with the increased levels of inflammatory markers COX2, iNOS, IL-1β and TNF-α, and
blunted IL-10 expression. Moreover, CD3 expression was increased in the hippocampus, consistently with FoxP3
and GITR. After chronic treatment of 3xTg-AD mice with an anti-TNFSF10 antibody, splenic FoxP3, GITR, and the
above-mentioned inflammatory markers expression was restored to basal levels, while expression of IL-10 was
increased. A similar picture was observed in the hippocampus. Such improvement of peripheral and CNS
inflammatory/immune response was associated with decreased microglial activity in terms of TNFα production, as
well as decreased expression of both amyloid and phosphorylated tau protein in the hippocampus of treated 3xTg-
AD mice. Interestingly, we also reported an increased expression of both CD3 and FoxP3, in sections from human
AD brain.
Conclusions: We suggest that neuroinflammation in the brain of 3xTg-AD mice triggered by TNFSF10 might result
in a more general overshooting of the immune response. Treatment with an anti-TNFSF10 antibody blunted
inflammatory processes both in the spleen and hippocampus. These data confirm the detrimental role of TNFSF10
in neurodegeneration, and corroborate the hypothesis of the anti-TNFSF10 strategy as a potential treatment to
improve outcomes in AD.
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Background
Alzheimer’s disease (AD) is the most common form of
dementia [1] and is characterized, besides a high burden
of disease, by substantial unmet need [2]. In fact, despite
the considerable number of attempts of introducing in-
novative neuroprotective treatments, such need remains
widely unsatisfied.
Although evidence shows that the anomalous protein
amyloid beta (Aβ), which exceedingly accumulates in the
hippocampus and other cerebral areas of the Alzheimer’s
brain, plays a pivotal role in the pathogenesis of the dis-
ease [3, 4], outcomes of Aβ-based clinical trials have
been, so far, deluding [5].
On the other hand, in the past two decades, laboratory
research has shed more light on various AD-related can-
didate pathogenetic factors, including superoxides [6, 7],
excitotoxicity [8, 9], as well as inflammation [10, 11]. In
this line, peripheral immune cells have more recently
been indicated as factors disrupting the immune equilib-
rium of the brain, potentially contributing to neurode-
generation [12].
Consistently, TNF-related apoptosis inducing ligand
(TNFSF10), a potent pro-apoptotic member of the
TNF superfamily also produced by injured neurons
[13] and activated glia [14], is known to modulate
cell-mediated immune response [15], for example, by
inducing an increase of the Treg cell subset of T lym-
phocytes [16], and it is in fact regarded as a critical
regulator of autoimmune T cells [17]. While there is
evidence that the blockade of TNFSF10 improves
pathology in models of multiple sclerosis, beneficial
effects in other neurological pathologies, included AD,
remain to be investigated [18].
In the AD brain, TNFSF10 sets into motion the in-
flammatory machinery, and mediates Aβ-induced neur-
onal death [19]. In fact, the role of TNFSF10 in Aβ-
related neurotoxicity has been demonstrated by different
studies showing that neutralization of TNFSF10 death
pathway protects human neuronal cell line from beta-
amyloid neurotoxicity [13], and, that the blockade of
the TNFSF10-death receptor DR5 with a specific
antibody completely prevents Aβ-induced neurotox-
icity in neuronal cells in vitro [20]. Moreover,
TNFSF-10 immunoreactivity has been detected in the
vicinity of Aβ plaques in post-mortem human AD
brains [21]. Consistently, age-related, Aβ-dependent
progression of cognitive decline is efficiently pre-
vented by chronic anti-TNFSF10 treatment in vivo in
the 3xTg-AD, a triple transgenic mouse model of
Alzheimer’s disease [19].
Such prominent neurotoxic effect of TNFSF10 relies
upon its capacity of redundantly recruiting other inflam-
matory cytokines, so to synergistically contribute to the
worsening of neuronal function [22].
Despite poor evidence is currently available regarding
the influence of peripheral immune response upon the
pathology of the AD brain and the related clinical out-
come [23, 24], more recent data indicate in fact that not
only peripheral immunocytes can enter the brain in
murine models of AD but also their modulation signifi-
cantly influence progression of brain pathology in the
same animals [12].
With such rationale, and with the aim to better high-
light a hypothetical prominent role of the peripheral im-
mune system in AD, we here investigate whether
immunoneutralization of TNFSF10 is related to a re-bal-
ance of both the central and the peripheral immune re-
sponse, and whether this could correlate with decreased
Aβ burden in the CNS, consistently with the previously
demonstrated improvement of the cognitive outcome in
3xTg-AD mice [19].
To accomplish this task, we used a triple transgenic
mouse model of AD (3xTg-AD), a strain homozygous
for the Psen1 mutation and homozygous for the co-
injected APPSwe and tauP301L transgenes, which pre-
sents an age-dependent increase of Aβ oligomer accu-
mulation, extracellular plaques in the cortex and the
hippocampus, and tau pathology paralleled by learning
and memory impairment [25]. Mice were treated chron-
ically, twice a month for 12 months with intraperitoneal
injection of an anti-TNFSF10 monoclonal antibody as
previously described [19], to evaluate the effects of
TNFSF10 neutralization, upon parameters of neuro-




Male 3xTg-AD mice [B6129-Psen1tm1MpmTg
(APPSwe, tauP30L) 1Lfa/J] [25] and wild-type mice
(B6129SF2/J) were purchased from Jackson Labo-
ratories. The 3xTg-AD, overexpressing mutant APP
(APPSwe), PSEN1 (PS1M146V), and hyperpho-
sphorylated tau (tauP301L), were originally generated
by co-injecting two independent transgene constructs
encoding human APPSwe and tauP301L (4R/0 N)
(controlled by murine Thy1.2 regulatory elements) in
single-cell embryos harvested from mutant homozy-
gous PS1M146V knock-in mice. Wild-type mice of
mixed genetic background 129/C57BL6 were used as
controls. These mice have been characterized and
described by Oddo et al. [25]. The animals were
maintained on a 12-h light/dark cycle in temperature- and
humidity-controlled rooms, and food and water were
available ad libitum. All experiments were carried out ac-
cording to the Directive 2010/63/EU and the Italian law
(D.Lgs. 26/2014), and were approved by the Italian Minis-
try of Health.
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Drug administration and experimental groups
Twenty 3xTg-AD and 20 wild-type mice were enrolled
at 3 months of age and four study groups were used: (i)
wild-type plus vehicle (Purified Rat IgG2ακ Isotype Con-
trol; BD Biosciences, San Jose, CA, USA); (ii) wild-type
plus TNFSF10-neutralizing antibody (Purified Rat Anti-
Mouse CD253;BD Biosciences); (iii) 3xTg-AD plus ve-
hicle; and (iv) 3xTg-AD plus TNFSF10-neutralizing anti-
body. Animals (ten per experimental group) were
administered with TNFSF10-neutralizing antibody (con-
centration: 0.05 mg/ml; 200 μl/ mouse; i.p.) or vehicle
(concentration: 0.05 mg/ml; 200 μl/ mouse; i.p.) twice a
month (Monday at 12 a.m.) and sacrificed at 15 months
of age 2-weeks after the last injection.
Human brain samples
Hippocampus tissue slides were obtained from four
healthy donors per group (two males, two females, age
59–85 years; post-mortem delay 5–8 h, hippocampal
CA2-CA3 subfields) who had no known history of
neurological or psychiatric disease. Human AD samples
were obtained from patients (two males, two females;
age 65–80 years; post-mortem delay 4–6 h; hippocampal
CA2-CA3 subfields). Tissues were purchased from
Abcam (Cambridge, UK).
Immunohistochemistry
For immunohistochemical analysis, sections were incu-
bated for 30 min in 0.3% H2O2/methanol to quench en-
dogenous peroxidase activity, then rinsed for 20 min
with phosphate-buffered saline (PBS; Bio-Optica, Italy).
High-temperature antigen unmasking was conducted
using a microwave oven.
Then, the sections were incubated with diluted rabbit
anti-beta-amyloid 1–42 (Merck Millipore, Darmstadt,
Germany). After overnight incubation in a humidified
chamber (4 °C), sections were incubated with the
secondary antibody (for 30 min at RT); detection was
performed with the Streptavidin-biotin method using 3,
3′-diaminobenzidine (DAB) as chromogen (LSAB 2
System-HRP, Dako, Denmark). Sections were counter-
stained with hematoxylin (Histolab Products AB, Gote-
borg, Sweden) mounted in GVA mount (Zymed,
Laboratories Inc., San Francisco, CA, USA) and
observed under an Axioplan (Zeiss, Germany) light
microscope and photographed with a digital camera
(Canon, Japan). The antibodies-staining (beta-amyloid
1–42) status was identified as either negative or positive.
Immunohistochemical positive staining was defined by
the presence of brown chromogen on the edge of the
hematoxylin-stained cell nucleus, distributed within the
cytoplasm or in the membrane via evaluation with light
microscope. Five fields of each sample, randomly
selected from each section, were analyzed for
morphometric and densitometric analysis. The percent-
age areas (morphometric analysis) stained with anti-
bodies (anti-beta-amyloid 1–42), expressed as % positive,
dark brown pixels of the analyzed fields, and the level
(high/low) of staining intensity of positive areas (densito-
metric analysis), expressed as densitometric count
(pixel2) of positive, dark brown pixels of the analyzed
fields, were calculated using an image acquisition soft-
ware (AxioVision Release 4.8.2—SP2 Software, Carl
Zeiss Microscopy GmbH, Jena, Germany). Digital
micrographs were taken using the Zeiss Axioplan light
microscope (Carl Zeiss, Oberkochen, Germany) fitted
with a digital camera (AxioCam MRc5, Carl Zeiss,
Oberkochen, Germany).
Protein extraction
Tissues were lysed in a lysis buffer containing 150 mM
NaCl, 50 mM Tris–HCl (pH 7.5), 5 mM EDTA, 1 mM
Na3VO4, 30 mM sodium pyrophosphate, 50 mM NaF,
1 mM acid phenyl-methyl-sulphonyl-fluoride, 5 μg/ml
aprotinin, 2 μg/ml leupeptin, 1 μg/ml pepstatin, 10%
glycerol, and 0.2% TritonTM X-100. The homogenates
were then centrifuged at 14,000 rpm for 10 min at 4 °C.
The protein concentration of the supernatant was deter-
mined by the Bradford method [26].
Western blot analysis
Equal amounts of protein (50 μg) were resolved by 8–12%
SDS-PAGE gels and transferred onto Hybond-ECL nitro-
cellulose membranes (GE Healthcare, Little Chalfont,
UK). Membranes were blocked at room temperature over-
night with a blocking solution composed of 5% nonfat dry
milk (Bio-Rad Laboratories, Segrate, Italy) in phosphate-
buffered saline plus 0.1% Tween 20 (PBS-T) and were
then probed with the following appropriate primary anti-
bodies: rabbit anti-beta-amyloid1–42 antibody (Merck
Millipore, Darmstadt, Germany); rabbit anti-TNFRSF10B
(Abcam); rabbit anti-TNFSF10 (Abcam); goat anti-
GITR (R&D Systems, Inc.); rat anti-FoxP3
(eBioscience, San Diego, CA, USA); rabbit anti-IL10
antibody (Abbiotec, San Diego, CA, USA); mouse anti-
COX2 (BD Biosciences); rabbit anti-NOS2 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA); goat anti-
IL-1β (R&D Systems, Inc.); and rabbit anti-TNF-α anti-
body (Abbiotec). After that, the membranes were
washed with PBS-T, and finally were probed with the
appropriate horseradish peroxidase-conjugated sec-
ondary antibodies (GE Healthcare) for 60 min at room
temperature in 5% non-fat dry milk (full details of the
antibodies used are reported in Additional file 8: Table
S1). For immunodetection, the membranes were ex-
posed to film after enhanced chemiluminescence
(ECL) (GE Healthcare). β-actin and β-tubulin (Santa
Cruz Biotechnology Inc.) were used as an internal
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control to validate the right amount of protein loaded
on the gels. Densitometric analysis of band intensity
was performed with the aid of ImageJ software
(https://imagej.nih.gov/ij/).
Immunofluorescence and confocal microscopy analysis
Splenic and hippocampal tissue specimens were fixed
overnight in 10% neutral-buffered formalin (Bio-Optica).
After overnight washing, they were dehydrated in graded
ethanol and paraffin-embedded taking care to preserve
their anatomical orientation. Tissue sections of 5 mm
were then cut and mounted on silanized glass slides and
air dried. To remove the paraffin, slides were immersed
in xylene two times, for 3 min each; rehydrated with
graded ethanol, 100%, 95%, 80%, 70%, and 50%, for
3 min each; and transferred to tap water. Antigens were
retrieved in sodium citrate buffer (10 mM sodium cit-
rate, 0.05% Tween-20, pH 6.0) by microwave for 15 min,
followed by rinsing with tap water. The slides were then
washed in PBS containing 0.25% Triton X-100 (PBST)
twice for 5 min each, blocked in PBST/1% BSA for 1 h
at room temperature, briefly rinsed with PBST, and in-
cubated at 4 °C overnight with the following primary
antibodies: a rabbit anti-CD3 antibody (Abcam), or a rat
anti-FoxP3 antibody (eBioscience), or a mouse anti-
GITR antibody (Santa Cruz Biotechnology Inc.), or a
rabbit anti-IL10 antibody (Abbiotec), or a rabbit anti-
beta-amyloid1–42 antibody (Merck Millipore), or a goat
anti-p-TAU antibody (Santa Cruz Biotechnology Inc.),
or a rat anti-CD11b antibody (Serotec, Kidlington, UK),
or a rabbit anti-TNF-α antibody (Abbiotec). Antibodies
were applied directly onto sections before overnight slide
incubation (4 °C) in a humid chamber. For fluorescence
visualization, after washing in PBS three times for 5 min
each, sections were incubated with the corresponding
fluorescent-labeled secondary antibodies at dark for 1 h
at room temperature: goat anti-mouse IgG-TR (Santa
Cruz Biotechnology Inc.); or goat anti-rat IgG antibody,
FITC conjugate (Merck Millipore); or goat anti-rabbit
IgG-TR (Santa Cruz Biotechnology Inc.); or Alexa Fluor
488 goat anti-rabbit IgG (Life Technologies, Carlsbad,
CA, USA); or Alexa Fluor 488 donkey anti-goat (Life
Technologies). See Additional file 8: Table S1 for full de-
tails of the antibodies used. Finally, for staining of nuclei
and stabilization of fluorescent signals, slides were cov-
ered in mounting medium (Fluoroshield with DAPI;
Sigma-Aldrich, Milan, Italy) and secured with a cover-
slip. Images were observed using a laser scanning con-
focal microscope (Zeiss LSM 700, Germany).
Qualitative and quantitative analysis for CD11b and
TNF-α immunoreactivity was performed using a Leica
4D confocal laser scanning microscope, equipped with
an argon–krypton laser. Confocal images were generated
and processed as described [27]. Volume of co-localized
elements was determined by Imaris 7.3 as previously de-
scribed [27]. Four regions of interest (x = 40 μm; y =
40 μm; z = 10 μm) were randomly chosen within each
slide and their respective volumes were calculated,
summed, and expressed as volume/μm3 [28].
Statistical analysis
Data were analyzed either by the one-way or the two-
way analysis of variance (ANOVA), followed, respect-
ively, by the Duncan’s least significant difference test or
by Bonferroni post-hoc test. Vertical bars are means ±
S.E.M. of at least three different experiments; signifi-
cance was set at a p value < 0.05 or p < 0.001. The graphs
were made using Graph Pad Prism (Ver. 7, La Jolla,
USA). Statistical evaluation was performed using stand-
ard computer software (SPSS software package, ver.
23.0, SPSS Inc., Chicago, IL, USA).
Results
Chronic anti-TNFSF10 treatment beneficially influences
body, spleen, and brain weight and decreases the
amount of amyloid beta in the spleen of 3xTg-AD mice
In light of the reported differences in the size of 3xTg-
AD animals compared to wild-type [29], we measured
the weight of the body, brains, and spleens, confirming
that while both body and brain weight were significantly
lower in 3xTg-AD mice vs. wild-type animals, spleens
weight was significantly augmented (Fig. 1a). Treatment
with the anti-TNFSF10 antibody resulted in increased
body and brain weight in 3xTg-AD animals and, on the
other hand, in a significant reduction of the spleen
weight (Fig. 1a–d).
Immunohistochemical and Western blot analysis per-
formed on spleen samples revealed specific immunore-
activity for amyloid beta 1–42 in AD vehicle (Fig. 2(a, C,
black arrows; b)) and AD anti-TNFSF10 (Fig. 2(a, D,
black arrows; b)) spleen sections, while spleens from
WT animals (untreated; treated with anti-TNFS10) did
not show any specific immunoreactivity for amyloid beta
1–42 (Fig. 2(a, A and B, respectively; b)).
Densitometric analysis showed that the expression of
amyloid beta 1–42 was significantly higher in untreated
AD animals compared to anti-TNFSF10 treated AD
animals (Fig. 2(a’, b’)).
Effects of chronic anti-TNFSF10 treatment on the
expression of either proinflammatory and anti-
inflammatory molecules in the spleen of 3xTg-AD mice
To corroborate the hypothesis that such changes in
3xTg-AD mice spleen could be related with impair-
ment of some proinflammatory parameters, Western
blot analysis was performed on spleen homogenates
for the expression of TNFSF10 and its receptor
TNFRSF10B, and that of the inflammatory molecules
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COX2, iNOS, IL-1β, TNF-α, the anti-inflammatory
cytokine IL-10, as well as that of the Treg lymphocyte
markers GITR and FoxP3.
The expression of COX2, iNOS, IL-1β, and TNF-α
was substantially increased in untreated 3xTg-AD
mice while treatment with the anti-TNFSF10 mono-
clonal antibody determined a significant attenuation
of their expression. On the other hand, the expression
of IL-10 was significantly increased in anti-TNFSF10-
treated animals. Furthermore, the expression of GITR
and Foxp3, constitutively highly expressed in the
spleen of untreated 3xTg-AD mice, was significantly
attenuated in animals undergone the anti-TNFSF10
treatment, as confirmed by densitometric analysis
(Fig. 3a, b).
In order to investigate the relationship between the
variation in the expression of both GITR and FoxP3,
we performed immunofluorescence of splenic sec-
tions from the same animals. Indeed, immunofluor-
escence confirmed that the expression of the two
molecules was higher in untreated 3xTg-AD mice
and it was decreased after treatment with the
anti-TNFSF10 antibody. Interestingly, GITR and
FoxP3 co-localized within the same cells (Fig. 3c,
white arrows).
The neuroinflammatory hallmarks in the hippocampus of
3xTg-AD mice are consistent with the splenic
inflammatory pattern and are modulated by the anti-
TNFSF10 treatment
In light of the observed splenic alterations, which
reflected objective impairment of the peripheral immune
response, we further investigated whether the spleen
findings could relate with the neuroinflammatory pro-
cesses in the hippocampus of the same animals. Thus,
we studied Treg cells profile markers by means of West-
ern blot analysis (and respective densitometry) in the
hippocampus. Robust expression of GITR and FoxP3
was detectable in the brain of untreated AD mice, while
treatment with the anti-TNFSF10 antibody resulted in
blunted expression of both GITR and FoxP3 (Fig. 4a).
In contrast, Western blot analysis (and relative den-
sitometry) showed that, while the expression of the
anti-inflammatory cytokine IL-10 was absent in the
hippocampus of 3xTg-AD mice, it became detectable in
animals undergone the anti-TNFSF10 treatment
(Fig. 4a).
Consistently, additional immunofluorescence experi-
ments demonstrated that, in the same hippocampal
areas, FoxP3 was abundantly expressed and co-localized
with GITR immunoreactivity in untreated 3xTg-AD
a
b c d
Fig. 1 Panel a (table): body, brain, and spleen weight changes in 15-month-old 3xTg-AD mice treated for 12 months with an anti-TNFSF10
monoclonal antibody (10 μg, i.p. twice a month). Panels b–d: comparison of body, brain and spleen weights in the same animals. *p < 0.05 vs WT
treated with vehicle; **p < 0.05 vs. untreated 3xTg-AD mice (one-way ANOVA, followed by a Duncan’s multiple range test). Vertical bars are
means ± S.E.M. WT wild-type (n = 10/group); AD: 3xTg-AD mice (n = 10/group)
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mice (Fig. 4b; white arrows). Treatment with the anti-
TNFSF10 antibody significantly reduced the expression
of both FoxP3 and GITR in the hippocampi of 3xTg-AD
mice (Fig. 4b). See Additional file 1: Figure S1 for nega-
tive controls.
Moreover, as the observed immune processes were
blunted by the anti TNFSF10 treatment, it was of
interest that the expression of IL-10 was increased
in 3xTg-AD mice treated with the anti TNFSF10
antibody, suggesting a setting into motion of the
anti-inflammatory response in the brain of the 3xTg-
AD animals, while FoxP3 expression was downregu-
lated (Fig. 4c; white arrows). See Additional file 2:
Figure S2 for negative controls.
To verify whether the expression of both GITR and
FoxP3 in the hippocampus of 3xTg-AD mice was associ-
ated with lymphocytes infiltration, immunostaining for
CD3 was performed in the CA2 and CA3 hippocampal
areas of untreated 3xTg-AD mice revealing a substantial
immunoreactivity in both areas as compared with wild
type mice. On the other hand, CD3 immunoreactivity
was reduced in the hippocampus of 3xTg-AD mice
treated with the anti TNFSF10 antibody compared to
untreated animals (Fig. 5a).
To better understand whether such decrease of CD3
immunoreactivity in the hippocampus of anti TNFSF10-
treated animals could be due to a decreased number of




Fig. 2 Panel (a): representative pictures of the immunohistochemical detection of Aβ1–42 expression (black arrows), in the spleen of 3xTg-AD
treated for 12 months with an anti-TNFSF10 monoclonal antibody (10 μg, i.p. twice a month). Photos A and B: respectively, wild-type mice
untreated, or treated with the anti-TNFSF10 antibody. Photos C and D: respectively 3xTg-AD mice untreated or treated with the anti-TNFSF10
antibody. The inserts in photos represent the respective areas magnified. Scale bar = 10 μM. Panel (a’): densitometric count of Aβ1–42
immunopositive cells. *p < 0.05 3xTg-AD mice untreated vs WT treated with vehicle; **p < 0.05 3xTg-AD mice treated with anti-TNFSF10 vs.
untreated 3xTg-AD mice (one-way ANOVA, followed by a Duncan’s multiple range test). Vertical bars are means ± S.E.M. WT wild-type (n = 5/
group); AD: 3xTg-AD mice (n = 5/group). Panel (b): Western blot analysis of Aβ1–42 in splenic homogenates. Panel (b’): Densitometric analysis of
the representative Western blot *p < 0.05 3xTg-AD mice untreated vs WT treated with vehicle; **p < 0.05 3xTg-AD mice treated with anti-TNFSF10
vs. untreated 3xTg-AD mice (one-way ANOVA, followed by a Duncan’s multiple range test). Vertical bars are means ± S.E.M. WT wild-type (n = 5/
group); AD: 3xTg-AD mice (n = 5/group)
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b
Fig. 3 (See legend on next page.)
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hippocampus), we performed specific immunofluores-
cence experiments and observed that FoxP3 expression
decreased following anti TNFSF10 treatment, in parallel
with decreased CD3 specific immunoreactivity (Fig. 5b).
See Additional file 3: Figure S3 for negative controls.
Expression of immune markers in the human AD brain
We asked whether changes in CD3, FoxP3, and
GITR immunoreactivity observed in the hippocam-
pus of the 3xTg-AD mice similarly occurred in the
brain of AD patients. Interestingly, immunohisto-
chemistry showed that while CD3 and FoxP3 were
absent in in the hippocampus from healthy individ-
uals (Fig. 6(a)), both proteins were detected in the
hippocampus from AD brain, showing a co-localized
immunostaining, consistently with the data obtained
in mice (Fig. 6(a; white arrows)). Furthermore, the
human AD hippocampus also expressed GITR,
which co-localized with FoxP3 (Fig. 6(b; white ar-
rows)). Respective densitometric counts are shown
in panels a’ and b’. See Additional file 4: Figure S4
and Additional file 5: Figure S5 for negative
controls.
Reactive proinflammatory microglia is blunted by the
anti-TNFSF10 treatment in 3xTg-AD mice
Chronically activated microglia and the related proin-
flammatory response play a pivotal role in AD neuro-
pathology [10]. Here, we showed confocal images of
the microglial marker CD11b, co-localized with the
proinflammatory cytokine TNF-α in the hippocampus
of mice treated as detailed above.
Microglia in untreated 3xTg-AD mice showed an acti-
vated morphology, as suggested by the cell body enlarge-
ment and ticker processes while in wild-type mice
microglia displayed a resting morphology. Moreover, un-
treated 3xTg-AD mice showed a dramatic increase in
microglial TNF-α, i.e., TNFα co-localized with CD11b,
as compared with WT mice (Fig. 7(a, A–C, G–I)). Of
note, the treatment with anti-TNFSF10, significantly
reduced TNF-α levels in microglia (Fig. 7(a, L–N)).
Expression of Aβ and phosphorylated-tau protein (p-tau)
are significantly attenuated in 3xTg-AD mice treated
chronically with anti TNFSF10
Amyloid beta and the phosphorylated tau protein are
recognize hallmarks of AD, as it is well established that
their amount correlates with the disease staging in the
AD brain [30] as well as in the 3xTg-AD model [25]. In
the light of our findings on the immune response in
3xTg-AD mice, we attempted to establish whether the
expression of both Abeta 1–42 (Fig. 8(a)) and p-tau
(Fig. 8(b)) paralleled the immune activity pattern ob-
served in the spleen and in the hippocampus of 3xTg-
AD mice. Immunohistochemical analysis showed that
both amyloid beta 1–42 and p-tau were abundantly
expressed in untreated 3xTg-AD mice, while their ex-
pression was greatly attenuated after treatment of the
animals with the anti-TNFSF10 antibody (Fig. 8). See
Additional file 6: Figure S6 and Additional file 7: Figure
S7 for negative controls.
Discussion
Here, we showed that 3xTg-AD mice with age-related
cognitive decline manifest also an imbalance of the im-
mune/inflammatory response.
We observed an increased spleen weight, as well as de-
creased brain and body weight in untreated 3xTg-AD
mice in their advanced age, confirming data from other
authors [29, 31]. At a first glance, one could argue that
such spleen enlargement could be due to the presence of
a transgene. However, the risk for genome insertion site-
related phenotypes and consequent splenomegaly is
highly unlikely, because APPswe and PS1M145V transgenes
are expressed but not translated in the spleen. In fact,
Oddo et al. [25] reported the absence of protein trans-
lates in various organs of the 3xTg-AD mouse, with the
exception of the central nervous system. In addition, it
has been reported that splenic alterations occur in 3xTg-
AD mice fairly ahead of the onset of the amyloid
pathology [29]. Accordingly, an altered rate of CD3 lym-
phocytes in the spleen has been reported, suggesting an
autoimmune/inflammatory involvement [29]. In this
line, light behavioral dysfunctions occurring in the early
(See figure on previous page.)
Fig. 3 Panel a: effects of the treatment with an anti-TNFSF10 monoclonal antibody on the expression of either TNFSF10, TNFRSF10B receptor,
proinflammatory, and anti-inflammatory molecules in the spleen of 3xTg-AD mice. Left blots: changes in the expression of TNFSF10 and its
TNFRSF10B receptor, as well as in GITR and Foxp3 and the anti-inflammatory cytokine IL-10 expression in 3xTg-AD mice, following chronic
treatment (12 months) with an anti-TNFSF10 monoclonal antibody (10 μg/animal twice a month, i.p.) or vehicle (10 μg/animal twice a month,
i.p.). Right blots: changes in the expression of the proinflammatory mediators COX2, iNOS, IL-1β, TNF-α in 3xTg-AD mice, following chronic
treatment (12 months) with an anti-TNFSF10 monoclonal antibody or vehicle (10 μg/animal twice a month, i.p.). Panel b: densitometric analysis of
respective western blots. *p < 0.05 vs untreated 3xTg-AD mice; **p < 0.05 vs. all other matching groups (one-way ANOVA, followed by a Duncan’s
multiple range test). Vertical bars are means ± S.E.M. Panel c: representative immunofluorescence photographs of mice spleens for GITR (red) and
FoxP3 (green) expression and co-localization of the two molecules (white arrows; merge column; DAPI = nuclear staining) in WT and 3xTg-AD
animals receiving either vehicle or an anti-TNFSF10 monoclonal antibody (10 μg/animal twice a month, i.p.) for 12 months. WT wild-type mice
(n = 5/group); AD: 3xTg-AD mice (n = 5/group)
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life of 3xTg-AD mice have been associated with the hu-
man parameters of minimal cognitive impairment
(MCI), with episodic memory loss in the absence of
major cognitive dysfunction [32].
Interestingly, an accumulation of human beta-amyloid
1–42 originating in the transgenic mouse brain was re-
vealed in the spleens of 3xTg-AD mice by immunohisto-
chemical and Western blot analysis. Although in this
mouse model beta-amyloid 1–42 and tau transgenes are
limited expressed by brain and spinal cord [25], different
reports showed that beta-amyloid 1–42 and tau are also
present in the blood and peripheral organs [33–36].
Therefore, we may speculate that over-accumulated
brain Aβ might be transported to peripheral organs [37],
thereby functioning as a signal to trigger peripheral im-
mune responses [38]. In this scenario, beta-amyloid
1–42 deposits in the spleen could be responsible for the
peripheral inflammation observed in the AD mice, and
for changes in immune cell setting, with special regard
to the increased CD3 population [31].
Consistently, we found that a set of inflammatory mol-
ecules, including TNFSF10, and its death receptor, as
well as COX2, iNOS, IL-1β, and TNF-α were signifi-
cantly increased in the spleen homogenates from 3xTg-
AD mice. It is also noteworthy that the splenic expres-
sion of the antigen GITR [39], as well as that of the Treg
cell-related transcription factor FoxP3 [40], were dra-
matically increased in the spleen of the same animals,
whereas the expression of the anti-inflammatory cyto-
kine IL-10 was negligible.
Now, keeping in mind the concept that molecules
from the CNS, such as Aβ, may influence also periph-
eral immune/inflammatory response [41], the exceed-
ing synthesis of Aβ in the brain could set into
motion specific immune response, as suggested by the
increased expression of splenic Treg markers GITR
and FoxP3. In fact, it is noteworthy that Treg cells
may suppress, for example, autoreactive T lympho-
cytes recruited in course of chronic inflammation
[42], which could be envisioned as a sort of feedback
mechanism to avoid overshooting of the immune/in-
flammatory response and tissue damage, as, for ex-
ample, activation of glucocorticoid secretion set into
motion by cytokines release in the course of an
immune/inflammatory response [39].
Although contrasting data are available on the role of
the GITR system in Treg setting [43], nevertheless, more
recent research has defined its role as a marker for hu-
man Treg cells [44], confirmed by data showing that
GITR could be regarded as a receptor belonging to the
immune checkpoint family [43]. In fact, it is known that
when Treg cell function is pharmacologically inhibited
by the immune checkpoint inhibitors, the restoration of
a balanced immune response is achieved, due to in-
activation of the Treg cells enabled by tumors [45].
TNFSF10 produced by macrophages is known to inter-
vene in immune processes, such as graft-versus-host
disease (GVHD), protection of privileged barriers, and
others [16]. In the same line, our results indicated that
high splenic expression of TNFSF10 was associated with
an increased GITR and FoxP3 expression in aged 3xTg-
AD mice. Consistently, the treatment with the anti-
TNFSF10 antibody resulted in a decreased expression of
Treg cells markers and in a significant attenuation of in-
flammatory molecules COX2, iNOS, IL-1β, and TNF-α,
with shrunk splenic volume. Similarly, there is evidence
that PD-1 checkpoint inhibitors can reduce brain
pathology and improve cognition in the AD murine
model [46].
Our data indeed confirm the potent inflammatory
properties of TNFSF10, mediated by its death receptor
TNFRSF10B [19], in peripheral organs, in which a
chronic inflammatory/immune response was set into
motion by a noxious challenge, such as Aβ, and support
the value of TNFSF10 neutralization in shutting the in-
flammatory process down [19, 47, 48].
Evidence shows that peripheral lymphocytes, including
Treg cells, are able to crawl across the BBB in neuro-
pathologic conditions [49]. In this line, we have pre-
viously shown that TNFSF10 is substantially expressed
in both the human AD brain [50], as well as in the
hippocampus of 3xTg-AD mice [19], and that its immu-
noneutralization by means of a monoclonal antibody
against TNFS10, is associated with an almost complete
recovery of cognitive capacities, along with blunted
expression of inflammatory mediators in the brain [19].
(See figure on previous page.)
Fig. 4 Effects of the treatment with an anti-TNFSF10 monoclonal antibody on the expression of GITR and FoxP3, as well as of the anti-
inflammatory protein IL-10 in the hippocampus of 3xTg-AD mice Panel a: Left: Western blot analysis of GITR, FoxP3, and IL-10 protein expression
in the mice following chronic treatment (12 months) with an anti-TNFSF10 monoclonal antibody (10 μg/animal twice a month, i.p.) or vehicle
(10 μg/animal twice a month, i.p.). Right: Densitometric analysis of Western blots. *p < 0.05 vs untreated 3xTg-AD mice; **p < 0.05 vs. all other
matching groups (one-way ANOVA, followed by a Duncan’s multiple range test). Vertical bars are means ± S.E.M. Panel b: representative
immunofluorescence images of hippocampi for GITR (red) and FoxP3 (green) expression and co-localization from the same animal groups as
above (white arrows; merge column; DAPI = nuclear staining). Panel c: immunofluorescence by confocal microscopy of hippocampi for IL-10 (red;
white arrows) and FoxP3 (green; white arrows) expression and co-localization from the same animal groups as above (merge column; DAPI =
nuclear staining). WT wild-type animals (n = 5/group); AD: 3xTg-AD animals (n = 5/group); the respective side columns are the lower magnification
samples where the areas to analyze (CA1, CA2, CA3, and CA4) were magnified (framed in a green box)
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Although poor evidence is currently available on the
influence of peripheral immune response upon the AD
brain pathology [23, 24], recent data indicate that not
only peripheral immunocytes have privileged gates to
enter the brain [51] but also they can significantly influ-
ence the progression of brain pathology in murine
models of AD [12]. More recently, a relationship has
been demonstrated between adaptive immune-related
impairment and AD neuropathology in the 3xTg-AD
mouse model, suggesting a causal role for typical Aβ and
tau pathologies [38].
Here, we showed high expression of FoxP3 and GITR
and their co-localization in the hippocampus of un-
treated 3xTg-AD mice while their expression was
attenuated by treatment with the anti-TNFSF10 anti-
body, suggesting that neutralization of TNFSF10, known
to increase the number and activity of Treg cells [16],
achieves a significant anti-inflammatory effect. In light of
the capability of TNFSF10 of recruiting other immune/
inflammatory mediators during the neurodegenerative
process [19, 47], it is noteworthy that also proinflamma-
tory mediators COX2, iNOS, IL-1β, and TNF-α were
downregulated by anti-TNFSF10 treatment along with
the increased levels of the anti-inflammatory cytokine
IL-10, [52], which is also produced by activated micro-
glia [53], injured neurons [54], and other cell types in
the CNS. In fact, it appears that IL-10 works as a pro-
tective tool in course of brain damage, likely to avoid
(See figure on previous page.)
Fig. 5 Confocal microscopy for detection of CD3 and FoxP3 positive cells in the hippocampus of 3xTg AD mice, following chronic treatment
(12 months) with an anti-TNFSF10 monoclonal antibody (10 μg/animal twice a month, i.p.) or vehicle (10 μg/animal twice a month, i.p.). Panel a:
each picture represents a single group of treatment and illustrates either the whole hippocampus (sagittal section) or, below, magnification of
CA2-CA3 areas displaying specific CD3 (green) immunofluorescence (magnifications of respective white frames) in the mice following chronic
treatment (12 months) with an anti-TNFSF10 monoclonal antibody (10 μg/animal twice a month, i.p.) or vehicle (10 μg/animal twice a month,
i.p.). Panel b: immunofluorescence of hippocampi for CD3 (red) and FoxP3 (green) expression and co-localization from the same animal groups as
above (merge column; DAPI = nuclear staining). The respective side columns are the lower magnification samples where the areas to analyze





Fig. 6 Confocal microscopy for detection of CD3, FoxP3, and GITR positive cells in the human AD brain (n = 4). Panel (a): CD3 (red) and FoxP3
(green) expression in the human AD brain and respective co-localization (white arrows; merge column; DAPI = nuclear staining). Panel (b): GITR
(red) and Foxp3 (green) expression in the human AD brain and respective co-localization (white arrows; merge column; DAPI = nuclear staining).
Panels (a’, b’): densitometric counts of immunopositive cells. *p < 0.001 vs. healthy human brain; (one-way ANOVA, followed by a Duncan’s
multiple range test). Vertical bars are means ± S.E.M.
Di Benedetto et al. Journal of Neuroinflammation          (2019) 16:166 Page 12 of 17
propagation of neuroinflammatory areas and related det-
rimental effects [55].
We also found that CD3 positive cells were significantly
represented in the hippocampus of untreated 3xTg-AD
animals, eventually returning to their basal expression
after the anti-TNFSF10 treatment. In addition, we also
demonstrated that FoxP3-specific immunofluorescence
was consistent with that of CD3. As postulated by other
authors, FoxP3-positive cells crossing into the brain could
create favorable conditions for an overshooting immune/
inflammatory response to Aβ [12]. In a similar line, a role
for Treg cells has been identified in other tissues chronic-
ally inflamed and in models of impaired immune response
[16, 56, 57]. This may partly account for the significant
attenuation of the inflammatory molecules in the brain
obtained by neutralization of TNFSF10, which also
recruits Treg cells [16], Interestingly, we showed that the
human post-mortem AD brain expressed CD3 (which was
not expressed by the healthy human brain), that co-local-
ized with FoxP3 and GITR, corroborating the hypothesis
that the AD brain is also characterized by the presence of
immunocytes, in analogy with other immune-related CNS
disorders [49].
Although there are no clinical data linking AD to
splenomegaly, prominent inflammatory and innate im-
mune responses have been observed in both AD and min-
imal cognitive impairment (MCI) [58–60]. Accordingly,
there are reports that suggest that circulating plasma
levels of cytokines are increased in AD [61, 62]. Moreover,
increased plasma levels of TNF-α have been associated
with scores in MMS [62]. More recently, an increase in
the CD4/CD8 ratio in 3xTg-AD mice was reported [38],
a
a’
Fig. 7 Confocal microscopy for detection of TNF-α and CD11b expression in the microglia of the CA2-CA3 regions of the hippocampus of 3xTg
AD mice, following chronic treatment (12 months) with an anti-TNFSF10 monoclonal antibody (10 μg/animal twice a month, i.p.; (n = 10/group)
or vehicle (10 μg/animal twice a month, i.p.). Representative images showing respectively CD11b (red, panels A, D, G, L), TNF-α (green, panels B, E,
H, M), and TNF-α co-localized with CD11b (panels C, F, I, N). Side graphic represents the densitometric count of positive cells; *p≤ 0.05 vs. all
other groups; (two-way ANOVA, followed by Bonferroni post-hoc test). Vertical bars are means ± S.E.M. WT wild-type animals (n = 5/group); AD:
3xTg-AD animals (n = 5/group). Black arrows point resting microglia; white arrows point activated microglia (panels G and I), or co-localization
TNF-α/CD11b (panels I and N)
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suggesting a deficit in the adaptive immune response con-
sistently with data reporting aberrant lymphocyte popula-
tions in AD individuals [63–68] .
Comparing the immunological scenario in the 3xTg-AD
animals with the data from human brains, it might be
speculated that neutralization of TNFSF10 may produces
beneficial effects through two possible mechanisms. The
first one relates to the decreased expression of the
inflammatory/immune mediators [16], with a second
alternative mechanism relating to the removal of the Treg
influence on immunocytes, allowing a re-balance of the
immune response and reduced brain accumulation of
Aβ [12].
The hypothesis of the restoration of a proper immune re-
activity in the hippocampus of 3xTg-AD mice by the anti-





Fig. 8 Effects of the treatment with an anti-TNFSF10 monoclonal antibody on the expression of either Aβ 1–42 (panel a) and phosphorylated Tau
protein (p-TAU) (panel b) in the hippocampus of 3xTg-AD mice: representative immunofluorescence images of hippocampi from each animal
group (merge column; DAPI = nuclear staining). The respective left-hand side columns are the samples where the areas to be magnified for
analysis were picked (green frame boxes; CA1, CA2, CA3, and CA4). Panels (a’, b’): densitometric count of immune-positive cells, for, respectively,
Aβ 1–42 and p-TAU. *p < 0.001 3xTg-AD mice untreated vs WT-vehicle; **p < 0.001 3xTg-AD mice treated with anti-TNFSF10 vs. untreated 3xTg-
AD mice (one-way ANOVA, followed by a Duncan’s multiple range test). Vertical bars are means ± S.E.M. WT wild-type animals (n = 5/group); AD:
3xTg-AD animals (n = 5/group)
Di Benedetto et al. Journal of Neuroinflammation          (2019) 16:166 Page 14 of 17
that proinflammatory microglia in 3xTg-AD mice was
blunted after anti-TNFSF10 treatment in the same area. As
known, activated microglia produces, in addition to
TNFSF10 [69], several inflammatory cytokines included
TNF-α [28], contributing to accelerate neuronal death [70].
Interestingly, microglia still displayed an activated morph-
ology after anti-TNFSF10, which likely relates to an in-
creased production of the anti-inflammatory cytokine IL-10
by these cells [27] . There is extensive evidence that micro-
glia is activated by noxious stimuli within the CNS [71], in-
cluding Aβ [72]. In addition, activated microglia has been
show to influence both humoral and cell-mediated periph-
eral immune response [73], through the release of cytokines
including TNF-α that may cross the BBB in the course of
neurodegenerative processes [49]. This clearly support the
hypothesis that soluble inflammatory molecules may influ-
ence tissues distant from the site of production [74]. Overall,
this result suggests that the anti-TNFSF10 treatment in-
duced a dampening of proinflammatory detrimental micro-
glia, while boosting the production of anti-inflammatory
molecules.
Restraint of the overall inflammatory/immune response
achieved by the anti-TNFSF10 treatment came along with
significantly decreased levels of both Aβ and p-Tau protein.
Immunofluorescence data showed significant decrease of
Aβ amounts in the hippocampus of 3xTg-AD mice treated
with the anti-TNFSF10 antibody, in parallel with significant
decrease of another AD hallmark, the hyperphosphorylated
Tau protein, known to substantially contribute to neuronal
death [61]. Cognitive decline is associated with a progres-
sively increasing amount of both proteins in the hippocam-
pus of 3xTg-AD animals [19]. Assuming that the Aβ excess
induces TNFSF10 expression in neurons [13], we suggest
that neutralization of TNFSF10 represents a potential strat-
egy to limit Aβ production, with consistent subsequent im-
provement of the cognitive outcome in AD [19].
Conclusions
In conclusion, the neurotoxic effects of TNFSF10 may
partly ensue from an unbalanced equilibrium of the over-
all immune response, triggered by Aβ which accumulates
in both the CNS and in the spleen. Aβ may be, at any rate,
the candidate antigenic challenge setting into motion a
systemic immune response associated with neuro-
inflammation. Re-trafficking of immunocytes between the
periphery and the brain [46] of 3xTg-AD mice might con-
tribute to neuroinflammation, with the involvement of
Treg cells. Neutralization of TNFSF10 may significantly
attenuate its detrimental effects along with those of other
inflammatory mediators in the brain; on the other hand,
decreased Treg cells in both the periphery and the brain
may enhance the activity of other cells such as macro-
phages/microglia and monocytes [12], to efficiently clear
Aβ from the brain tissue [75].
Finally, our data demonstrate that TNFSF10 substan-
tially cooperates with other cytokines in sustaining in-
flammation in the 3xTg-AD mouse brain. TNFSF10 also
inhibits the beneficial activity of the immune response
by recruiting Treg cells, resulting in the inhibition of the
anti-inflammatory machinery. Blockade of TNFSF10
may thus be envisioned as an innovative treatment of
neurodegeneration in AD.
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